Italy Diabetes Drugs and Devices Market Introduction and Overview
According to SPER Market Research, the Italy Diabetes Drugs and Devices Market is estimated to reach USD 1.85 billion by 2033 with a CAGR 6.31%.
The report includes an in-depth analysis of the Italy Diabetes Drugs and Devices Market, including market size and trends, product mix, distribution channels, and supplier analysis. The wide subject of diabetes treatment includes medications and equipment designed to regulate blood sugar levels and lessen related problems. Cornerstone medications include metformin, sulfonylureas, and insulin analogs; they all address different facets of glucose management. First-line treatment with metformin improves insulin sensitivity and reduces the liver's synthesis of glucose. Sulfonylureas cause pancreatic beta cells to secrete more insulin. By simulating the natural patterns of insulin production, insulin analogs provide accurate regulation of blood sugar levels.
- The most innovative insulin delivery device available, the Insulin Pen 2.0TM, was introduced by wearable diabetes technology leader Cequr in June 2022. The pen's compact size allows the user to wear it on their body at all times. In order to help users monitor their blood sugar levels throughout the day, it also has an integrated blood glucose meter.
- New Roche point-of-care blood glucose monitor for hospital staff was introduced in January 2022. It comes with a companion device that resembles a touchscreen smartphone and is used to run the device's apps. In addition to a camera and a touchscreen for recording additional diagnostic data, the portable Cobas pulse has an automatic glucose test strip reader. All patient types, including those in intensive care and infants, can use it.
Market Opportunities and Challenges
Opportunities: The rise in diabetes cases and the shift toward an urbanized, sedentary lifestyle are the main factors propelling the growth of the diabetes care devices market. Additionally, the need for quick and safe diagnosis, an increase in diabetes treatments, a growth in the number of people with diabetes worldwide, and technical developments in the field of diabetes devices will drive the diabetic care market throughout the projection period.
Automated glucose monitoring systems known as continuous glucose monitoring devices are made up of a tiny, adhesive patch-attached gadget that can be worn on the body. The sensor portion of the apparatus measures glucose levels by using interstitial fluid samples collected through a cannula placed into the epidermis. A transmitter that may wirelessly transfer data to a smartphone or other specialized mobile receiving device is attached to sensors. Because CGM reduces disruptions and promotes greater sleep, controlling blood glucose levels is made much simpler. By lessening the overall mental strain of controlling diabetes, it also enhances the mental health of patients or caregivers.
Challenges: A significant challenge is the financial strain that diabetes and its consequences place on the healthcare system. Along with the rising costs of treating diabetes-related consequences including neuropathy and cardiovascular diseases, Italy, like many other nations, struggles with the rising costs of managing diabetes, including drugs and devices. Furthermore, the adoption of novel diabetes medications and technologies may be impeded by regulatory barriers and payment regulations, which would restrict patient access to state-of-the-art care.
Market Competitive Landscape
Companies such as Abbott, Novo Nordisk, Dexcom, Medtronic, and others, along with other generic companies, dominate the semi-consolidated Italian market for diabetes care devices.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Management Devices, By Monitoring Devices
|
| Regions covered | Eastern Region, Western Region, Northern Region, Southern Region
|
| Companies Covered | Abbott Diabetes Care, Arkray Inc., Ascensia Diabetes Care, Dexcom, Insulet Corporation, Eli Lilly, LifeScan Inc., Medtronic, Novo Nordisk A/S, Roche Diabetes Care, Rossmax International Ltd., Sanofi. |
COVID-19 Impact on Italy Diabetes Drugs and Devices Market
Italy's diabetic care devices have been severely hit by the COVID-19 outbreak. The epidemic brought to light prospects for advancing and broadening advances in the provision of diabetes care, including the use of diabetes technology and virtual consultations between healthcare professionals and individuals with diabetes. Crisis management has eliminated several long-standing regulatory restrictions and sparked previously unheard-of demand in remote care from both patients and clinicians. Consequently, the COVID-19 pandemic accelerated the expansion of the diabetic care device industry.
Key Target Audience:
- Patients with diabetes
- Healthcare professionals (doctors, nurses, pharmacists, etc.)
- Hospitals and clinics
- Pharmaceutical companies
- Medical device manufacturers
- Research institutions and academia
- Government health agencies
- Insurance companies
Our in-depth analysis of the Italy Diabetes Drugs and Devices Market includes the following segments:
|
By Management Devices:
|
Insulin Pump
Insulin Syringes
Cartridges in Reusable Pens
Insulin Disposable Pens
Jet Injectors
|
|
By Monitoring Devices:
|
Self-Monitoring Devices
Continuous Glucose Monitoring
|
Key Topics Covered in the Report:
- Italy Diabetes Drugs and Devices Market Size (FY’2024-FY’2033)
- Overview of Italy Diabetes Drugs and Devices Market
- Segmentation of Italy Diabetes Drugs and Devices Market By Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, Jet Injectors)
- Segmentation of Italy Diabetes Drugs and Devices Market By Monitoring Devices (Self-Monitoring Devices, Continuous Glucose Monitoring)
- Expansion Analysis of Italy Diabetes Drugs and Devices Market
- Problems and Obstacles in Italy Diabetes Drugs and Devices Market
- Competitive Landscape in the Italy Diabetes Drugs and Devices Market
- Impact of COVID-19 and Demonetization on Italy Diabetes Drugs and Devices Market
- Details on Current Investment in Italy Diabetes Drugs and Devices Market
- Competitive Analysis of Italy Diabetes Drugs and Devices Market
- Prominent Players in the Italy Diabetes Drugs and Devices Market
- SWOT Analysis of Italy Diabetes Drugs and Devices Market
- Italy Diabetes Drugs and Devices Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Italy Diabetes Drugs and Devices Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Italy Diabetes Drugs and Devices Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Italy Diabetes Drugs and Devices Market
7. Italy Diabetes Drugs and Devices Market, By Management Devices (USD Million) 2020-2033
7.1. Italy Diabetes Drugs and Devices Market Size, Share and Forecast, By Management Devices, 2020-2026
7.2. Italy Diabetes Drugs and Devices Market Size, Share and Forecast, By Management Devices, 2027-2033
7.3. Insulin Pump
7.3.1. Insulin Pump device
7.3.2. Insulin Pump Reservoir
7.3.3. Infusion Set
7.4. Insulin Syringes
7.5. Cartridges in Reusable Pens
7.6. Insulin Disposable Pens
7.7. Jet Injectors
8. Italy Diabetes Drugs and Devices Market, By Monitoring Devices (USD Million) 2020-2033
8.1. Italy Diabetes Drugs and Devices Market Size, Share and Forecast, By Monitoring Devices, 2020-2026
8.2. Italy Diabetes Drugs and Devices Market Size, Share and Forecast, By Monitoring Devices, 2027-2033
8.3. Self-Monitoring Devices
8.3.1. Glucometer Devices
8.3.2. Blood Glucose Test Strips
8.3.3. Lancets
8.4. Continuous Glucose Monitoring
8.4.1. Sensors
8.4.2. Durables
9. Italy Diabetes Drugs and Devices Market Forecast, 2020-2033 (USD Million)
9.1. Italy Diabetes Drugs and Devices Market Size and Market Share
10. Italy Diabetes Drugs and Devices Market, By Region, 2020-2033 (USD Million)
10.1. Italy Diabetes Drugs and Devices Market Size and Market Share By Region (2020-2026)
10.2. Italy Diabetes Drugs and Devices Market Size and Market Share By Region (2027-2033)
10.3. Eastern Region
10.4. Northern Region
10.5. Eastern Region
10.6. Western Region
11. Company Profile
11.1. Abbott Diabetes Care
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Arkray Inc.
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Ascensia Diabetes Care
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Dexcom
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Insulet Corporation
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Eli Lilly
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. LifeScan Inc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Medtronic
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Novo Nordisk A/S
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Roche Diabetes Care
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Rossmax International Ltd.
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Sanofi
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Others
12. Conclusion
13. Reference Links
14. List of Abbreviations
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
